Volume 32, Issue 4 (July 2021)
Studies in Medical Sciences 2021, 32(4): 303-312 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Vazifekhah S, Rangarzan Z, Dehghan K. EVALUATING THE SIDE EFFECTS OF MATERNAL MAGNESIUM SULFATE RECEIVED IN PRE-ECLAMPSIA IN TERM AND LATE-TERM NEONATES IN 2015 AND 2016. Studies in Medical Sciences 2021; 32 (4) :303-312
URL: http://umj.umsu.ac.ir/article-1-5457-en.html
URL: http://umj.umsu.ac.ir/article-1-5457-en.html
Associate Professor of Neonatal and Perinatal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , drresearch646@gmail.com
Abstract: (5000 Views)
Background & Aims: Using magnesium sulfate might prevent the seizure, it could lead to poisoning in the patient. The present study aims at evaluating the side effects of maternal magnesium sulfate consumption in pre-eclampsia on term and late-preterm neonates.
Materials & Methods: This is a retrospective descriptive analytical study. One hundred term (group 1) and 100 late-preterm neonates (group 2) that were born in Shahid Motahari hospital of Urmia University of Medical Sciences from mothers with pre-eclampsia who had received magnesium sulfate, and as the control group, 100 neonates from mothers with pre-eclampsia who had not received magnesium sulfate (group 3) entered the study with easy and available sampling.
Results: The mean duration of sulfate uptake in the first group was 8.96±9.80 days and in the second group was 27.66±15.23 days and this difference was significant (p = 0.035). In the first group, 94 infants (94%), in the second group, 21 infants (21%), and in the third group, 64 infants (64%) did not need breathing support, which showed a significant difference between the groups (p <0.001). The first and fifth minute Apgar scores were significantly lower in the second group than in the first group and control, but this difference was not significant (p >0.05).
Conclusion: The findings of the present study depicted that magnesium sulfate administered for pre-eclampsia does not lead to neonates’ hypotonia, more admission days in the ward or NICU, and low Apgar scores.
Materials & Methods: This is a retrospective descriptive analytical study. One hundred term (group 1) and 100 late-preterm neonates (group 2) that were born in Shahid Motahari hospital of Urmia University of Medical Sciences from mothers with pre-eclampsia who had received magnesium sulfate, and as the control group, 100 neonates from mothers with pre-eclampsia who had not received magnesium sulfate (group 3) entered the study with easy and available sampling.
Results: The mean duration of sulfate uptake in the first group was 8.96±9.80 days and in the second group was 27.66±15.23 days and this difference was significant (p = 0.035). In the first group, 94 infants (94%), in the second group, 21 infants (21%), and in the third group, 64 infants (64%) did not need breathing support, which showed a significant difference between the groups (p <0.001). The first and fifth minute Apgar scores were significantly lower in the second group than in the first group and control, but this difference was not significant (p >0.05).
Conclusion: The findings of the present study depicted that magnesium sulfate administered for pre-eclampsia does not lead to neonates’ hypotonia, more admission days in the ward or NICU, and low Apgar scores.
References
1. Aali BS, Ghafoorian J, Mohamad-Alizadeh S. Severe preeclampsia and eclampsia in Kerman, Iran: complications and outcomes. Medical Science Monitor 2004;10(4):CR163-7. [Google Scholar]
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. New England journal of medicine 2004 ;350(7):672-83. [DOI:10.1056/NEJMoa031884] [PMID]
3. F Gary C. Williams Obstetrics 24th Edition. Medical; 2014. [Google Scholar]
4. Majidi S, Haki BK, Matlabi H. Factors Affecting Blood Pressure in Women with Hypertension Who Were Referred to Beyrag Health House-Tabriz 1391. Depiction of Health 2013;4(1):21-6. [Google Scholar]
5. Zalak K, Kazemi Haki B, Matlabi H. Obstacles to Self-Care From The Viewpoint of TypeII Diabetic Patients and Guidelines to Remove Them. Jorjani Biomedicine Journal 2012; 10(1):30-7. [Google Scholar]
6. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004;190(6):1520-6. [DOI:10.1016/j.ajog.2003.12.057] [PMID]
7. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician 2004;70(12):2317-24. [URL]
8. Belfort MA, Clark SL, Sibai B. Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstet Gynecol Surv 2006;61(10):655-65. [DOI:10.1097/01.ogx.0000238670.29492.84] [PMID]
9. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193(1):153-63. [DOI:10.1016/j.ajog.2004.11.059] [PMID]
10. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000;183(3):717-25. [DOI:10.1067/mob.2000.106581] [PMID]
11. Abbassi-Ghanavati M, Alexander JM, McIntire DD, Savani RC, Leveno KJ. Neonatal effects of magnesium sulfate given to the mother. Am J Perinatol 2012;29(10):795-9. [DOI:10.1055/s-0032-1316440] [PMID]
12. Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection: A meta-analysis based on prisma guidelines. Medicine (Baltimore) 2016;95(1):e2451. [DOI:10.1097/MD.0000000000002451] [PMID] [PMCID]
13. Sherwin CM, Balch A, Campbell SC, Fredrickson J, Clark EA, Varner M, et al. Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic Clin Pharmacol Toxicol 2014;114(4):318-22. [DOI:10.1111/bcpt.12166] [PMID] [PMCID]
14. Costantine MM, Weiner SJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU).). Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 2009;114(2 Pt 1):354-64. [DOI:10.1097/AOG.0b013e3181ae98c2] [PMID] [PMCID]
15. Kamyar M, Manuck TA, Stoddard GJ, Varner MW, Clark E. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. BJOG 2016;123(7):1161-6. [DOI:10.1111/1471-0528.13460] [PMID]
16. Mittendorf R, Dambrosia J, Pryde PG, Lee K-S, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002;186(6):1111-8. [DOI:10.1067/mob.2002.123544] [PMID]
17. Stone SR, Pritchard JA. Effect of maternally administered magnesium sulfate on the neonate. Obstet Gynecol 1970;35(4):574-7. [Google Scholar]
18. Ambadkar A, Prasad M, Chauhan AR. Neonatal effects of maternal magnesium sulphate in late preterm and term pregnancies. J Obstet Gynaecol India 2019;69(1):25-30. [DOI:10.1007/s13224-017-1074-4] [PMID] [PMCID]
19. Greenberg MB, Penn AA, Thomas LJ, El-Sayed YY, Caughey AB, Lyell DJ. Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. Am J Obstet Gynecol 2011;204(6): 515.e1-7. [DOI:10.1016/j.ajog.2011.01.046] [PMID]
20. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359(9): 895-905. [DOI:10.1056/NEJMoa0801187] [PMID] [PMCID]
21. Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol2009;113(6): 1327-33. [DOI:10.1097/AOG.0b013e3181a60495] [PMID]
22. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol2009; 200(6): 595-609. [DOI:10.1016/j.ajog.2009.04.005] [PMID] [PMCID]
23. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Jama 2003; 290(20): 2669-76. [DOI:10.1001/jama.290.20.2669] [PMID]
24. Eftekhari J, Kazemi Haki B, Tizro P, Alizadeh V. A comparison to facilitate insertion of the laryngeal mask: term of recovery and postoperative nausea and vomiting after anesthesia with propofol-atracurium and thiopental-atracurium. Acta Med Iran 2015;53(2): 117-21. [Google Scholar]
25. Sane S, Aghdashi MM, Kazemi Haki B, Gholamveisi B, Rajabzadeh M, Golabi P. The effect of pregabalin on the prevention of succinylcholine-induced fasciculation and myalgia. J Perianesth Nurs 2020;35(3): 255-9. [DOI:10.1016/j.jopan.2019.11.005] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
